drugset / Trial / NCT00564928
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine: * Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. * Group A - subjects who have not previously received chemotherapy * Group B - sujects who have received prior chemotherapy or could not tolerate chemotherapy. * Clinical response will be determined by PSA and radiological response
Timeline
- Start
- 2007-11
- Primary completion
- 2010-03
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | retaspimycin | Small molecule | 400 mg/m2 | Intravenous |